Yartemlia Ramp Accelerates as Omeros Turns Cash-Flow Positive and Slashes Debt
First full quarter of Yartemlia sales, a 43% note reduction, and positive operating cash flow signal a new phase for this biotech
OMER · Earnings Call · 2026-08-12
Yartemlia Ramp Accelerates
The second quarter of 2026 marked Omeros' first full quarter of Yartemlia (narsoplimab) sales, and the numbers are striking. “Yartemlia generated $32.2 million in gross sales in its first full quarter on the market” — Gregory A. Demopulos, CEO or President · 2026-08-12, with net sales of $28.5M and a gross-to-net adjustment of 11.5%. That's a 190% jump in gross sales versus Q1, when the launch was just getting underway. The ramp is not just about volume; the patient mix is shifting toward adults. “adult patients represented approximately 75% of Yartemlia sales” — Gregory A. Demopulos, CEO or President · 2026-08-12. This is a critical inflection point because TA-TMA historically skews 85% adult, and early adoption had been disproportionately pediatric. In the Q1 call, management had noted “we are seeing a greater percentage of these patients being pediatric than the 15% that you cited” — Gregory Demopulos, Chief Executive Officer · 2026-05-13; now the adult share is closing in on the historical split. adult transplant centers are engaging at a rapid pace — 73 unique accounts ordered by June 30, up 143% since March 31. The reimbursement tailwinds are also firming up. CMS assigned a permanent J-code effective July 1, and the final IPPS rule granted the NTAP for Yartemlia, providing up to $287K per inpatient treatment. As Gregory noted, “The NTAP is particularly important because Medicare beneficiaries represent approximately 30% of U.S. allogeneic transplant recipients” — Gregory A. Demopulos, CEO or President · 2026-08-12. This removes a major access barrier and should accelerate adoption further.Capital Structure and Cash Flow Turn Positive
Perhaps the most telling change this quarter is the turn to positive operating cash flow. “operations generated $4.1 million of positive cash flow during the quarter” — Gregory A. Demopulos, CEO or President · 2026-08-12. That is a meaningful milestone for a company that has been R&D-heavy for years. Management also took aggressive steps to de-risk the balance sheet: they repurchased $30.5M of the 9.5% convertible notes due 2029, cutting outstanding principal by 43% to $40.3M, and retired 843K shares year-to-date. These actions reduce future interest expense and potential dilution. As CEO Greg Demopulos said on the call, “we hold to our statement previously that by mid 27, we expect to be cash flow positive company wide” — Gregory A. Demopulos, CEO or President · 2026-08-12. The note repurchases are a fresh theme — they didn't appear in prior calls to this degree, reflecting a new confidence in the commercial trajectory. The financial statements reflect this shift. While the fundamentals file (as of Q1 2026) shows negative operating income, the Q2 call reveals a swing to positive GAAP net income of $200K, with adjusted net income of $1.8M. The company ended the quarter with $132M in cash and investments. Effective net cash improved from a negative position in early 2025 to a comfortable cushion, giving Omeros runway to fund its pipeline.Beyond the Launch: MASP-2 Platform Expansion
Yartemlia is just the first commercial asset from a broader Lectin Pathway franchise. Management emphasized that the drug's mechanism — inhibiting MASP-2 upstream of complement — avoids the infection risks associated with C5 inhibitors, a key differentiator as competitors like AstraZeneca's Ultomiris miss endpoints in TA-TMA. The company is already planning expansion into hyperinflammatory ARDS, prophylactic pediatric TATMA, and other endothelial injury syndromes. On the call, Gregory described the shift in diagnostic thinking:This is a long-term opportunity, as diagnosis of exclusion historically kept incidence rates understated. Beyond TATMA, Omeros is advancing a long-acting MASP-2 antibody (OMS103) and an oral small-molecule MASP-2 inhibitor, plus its OncotoX-AML and TCAT platforms. The pipeline breadth is a reminder that this is not a one-product story. The outlook remains positive, and management reiterated its expectation that Yartemlia becomes the standard of care — a target stated back in May: “We do expect that YARTEMLEA will become standard of care for the treatment of TA-TMA” — Gregory Demopulos, Chief Executive Officer · 2026-05-13. The market is taking notice: the stock has rallied ~68% over the past 90 days, with a particularly strong +70% surge in the last three weeks, breaking out from a multi-year base. The market is pricing in a successful launch and the balance sheet improvement, but the key question remains whether Yartemlia can sustain this pace as it scales.We are working to shift that paradigm toward proactive screening, enabling clinicians to identify and treat more patients earlier and ultimately improve transplant outcomes.